• We understand what we write


URL links to publications:

Schmitz S, Hamoir M. Emergency percutaneous tracheotomy. In book: Percutaneous Tracheostomy in Critically Ill Patients, Jan 2016: pp.91-96

Seront E, Rottey S, Filleul B et al. Phase II study of dual phosphoinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor BEZ235 in patients with locally advanced or metastatic transitional cell carcinoma (TCC). BJU Int 2016; Jan 18. doi: 10.1111/bju.13415. [Epub ahead of print]

Schmitz S, Duhoux F, Machiels JP. Window of opportunity studies: do they fulfil our expectations? Cancer Treat Rev 2016 Feb;43:50-7. doi: 10.1016/j.ctrv.2015.12.005. Epub 2015 Dec 31.

Schmitz S, Machiels JP. Targeting the tumour environment in squamous cell carcinoma of the head and neck. Curr Treat Options Oncol 2016 Jul;17(7):37. doi: 10.1007/s11864-016-0412-6.

Dermine A, Machiels JP. Treatment landscape of metastatic prostate cancer: the role of Radium 223. Acta Clin Belg 2016 Jul 4:1-5. [Epub ahead of print] DOI: 10.1080/17843286.2016.1203545.

Seront E, Machiels JP. Molecular biology and targeted therapies for urothelial carcinoma. Cancer Treat Rev 2015 Apr;41(4):341-53. doi: 10.1016/j.ctrv.2015.03.004. Epub 2015 Mar 24. 

Eiszele, A. Improving compliance rates in hand hygiene: The Australian experience. Medical Experts Online 2015.

Schmitz S, Bindea G, Albu RI et al. Cetuximab promotes epithelial to mesenchymal transition and cancer associated fibroblasts in patients with head and neck cancer. Oncotarget 2015 Oct 27;6(33):34288-99. doi: 10.18632/oncotarget.5924

Carrasco J, Gizzi M, Pairet G et al. Pathological responses after angiogenesis or EGFR inhibitors in metastatic colorectal cancer depend on the chemotherapy backbone. Br J Cancer 2015; 113: 1298 - 1304.

Gizzi M, Selda A, Machiels JP. Tubulocystic Carcinoma of the Kidney with Fatal Outcome in an Adolescent Male. Urol Int 2015; 94:485-487

Schmitz S, Rommel D, Michoux N et al. Dynamic contrast-enhanced computed tomography to assess early activity of cetuximab in squamous cell carcinoma of the head and neck. Radiol Oncol 2015 Mar; 49(1): 17 - 25

Schmitz S, Hamoir M, Reychler H et al. Tumour response and safety of cetuximab in a window pre-operative study in patients with squamous cell carcinoma of the head and neck. Ann Oncol 2013;24(9): 2261-2266 First published online May 23, 2013 doi:10.1093/annonc/mdt180

Schmitz S, Ang K, Vermorken J et al. Targeted therapies for squamous cell carcinoma of the head and neck: Current knowledge and future directions. Cancer Treat Rev 2014 Apr;40(3):390-404. doi: 10.1016/j.ctrv.2013.09.007. Epub 2013 Sep 14.

Schmitz S, Daminsky-Forrett M-C, Henry S., et al. Phase II study of figitumumab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: clinical activity and molecular response (GORTEC 2008-02) Ann Oncol 2012;23(8): 2153-2161 First published online January 10, 2012 doi:10.1093/annonc/mdr574

Machiels JP, Mazzeo F, Clausse M et al. Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer. J Clin Oncol 2008; 26: 5261-5268

Personeni N, Fieuws S, Piessevaux H et al. Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab : A fluorescent in situ hybridization study. Clin Cancer Res 2008;14(18): 5869-5876

Personeni, N. Outcome prediction to erlotinib in gastroesophageal adenocarcinomas: can we improve epidermal growth factor receptor and phospho-AKT testing? J Clin Oncol 2007; 25: 910

Personeni, N. Epidermal growth factor receptor gene copy number in esophageal cancer and outcome preditction to gefitinib: does intrtumoral heterogeneity matter? J Clin Oncol 2006; 24: 5465